Combined with the proteomic analysis of the four groups of CD138+ plasma cells, a highly significant differential proteomic signature between the four chemosensitivity profiles was identified, thus opening the way to a theranostic approach to patient treatment.
← all excerpts
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.
1
—
—